Parhofer KG - Search Results

1

Chemerin is associated with markers of inflammation and components of the metabolic syndrome but does not predict coronary atherosclerosis.

Lehrke M, Becker A, Greif M, Stark R, Laubender RP, von Ziegler F, Lebherz C, Tittus J, Reiser M, Becker C, Göke B, Leber AW, Parhofer KG, Broedl UC. Lehrke M, et al. Among authors: parhofer kg. Eur J Endocrinol. 2009 Aug;161(2):339-44. doi: 10.1530/EJE-09-0380. Epub 2009 Jun 4. Eur J Endocrinol. 2009. PMID: 19497986

2

Effects of phytosterol ester-enriched margarine on plasma lipoproteins in mild to moderate hypercholesterolemia are related to basal cholesterol and fat intake.

Mussner MJ, Parhofer KG, Von Bergmann K, Schwandt P, Broedl U, Otto C. Mussner MJ, et al. Among authors: parhofer kg. Metabolism. 2002 Feb;51(2):189-94. doi: 10.1053/meta.2002.29988. Metabolism. 2002. PMID: 11833047 Clinical Trial.

3

[Glinides and glitazones in diabetes treatment. Are they really effective?].

Parhofer KG, Göke B. Parhofer KG, et al. MMW Fortschr Med. 2002 May 2;144(18):34-6, 38-9. MMW Fortschr Med. 2002. PMID: 12422705 German.

4

Comparison of current guidelines for primary prevention of coronary heart disease: risk assessment and lipid-lowering therapy.

Broedl UC, Geiss HC, Parhofer KG. Broedl UC, et al. Among authors: parhofer kg. J Gen Intern Med. 2003 Mar;18(3):190-5. doi: 10.1046/j.1525-1497.2003.20207.x. J Gen Intern Med. 2003. PMID: 12648250 Free PMC article.

5

Effect of atorvastatin on lipid parameters, LDL subtype distribution, hemorrheological parameters and adhesion molecule concentrations in patients with hypertriglyceridemia.

Empen K, Geiss HC, Lehrke M, Otto C, Schwandt P, Parhofer KG. Empen K, et al. Among authors: parhofer kg. Nutr Metab Cardiovasc Dis. 2003 Apr;13(2):87-92. doi: 10.1016/s0939-4753(03)80023-6. Nutr Metab Cardiovasc Dis. 2003. PMID: 12929621

6

[Therapy of hyperlipoproteinemia in the elderly].

Parhofer KG, Göke B. Parhofer KG, et al. Internist (Berl). 2003 Aug;44(8):968-76. doi: 10.1007/s00108-003-0942-4. Internist (Berl). 2003. PMID: 14671811 Review. German.

7

Effect of pioglitazone on lipids in well controlled patients with diabetes mellitus type 2 -- results of a pilot study.

Parhofer KG, Otto C, Geiss HC, Laubach E, Göke B. Parhofer KG, et al. Exp Clin Endocrinol Diabetes. 2005 Jan;113(1):49-52. doi: 10.1055/s-2004-830527. Exp Clin Endocrinol Diabetes. 2005. PMID: 15662596 Clinical Trial.

8

Increase in adiponectin levels during pioglitazone therapy in relation to glucose control, insulin resistance as well as ghrelin and resistin levels.

Otto C, Otto B, Göke B, Pfeiffer AF, Lehrke M, Vogeser M, Spranger J, Parhofer KG. Otto C, et al. Among authors: parhofer kg. J Endocrinol Invest. 2006 Mar;29(3):231-6. doi: 10.1007/BF03345545. J Endocrinol Invest. 2006. PMID: 16682836

9

Genetic variants of adiponectin receptor 2 are associated with increased adiponectin levels and decreased triglyceride/VLDL levels in patients with metabolic syndrome.

Broedl UC, Lehrke M, Fleischer-Brielmaier E, Tietz AB, Nagel JM, Göke B, Lohse P, Parhofer KG. Broedl UC, et al. Among authors: parhofer kg. Cardiovasc Diabetol. 2006 May 15;5:11. doi: 10.1186/1475-2840-5-11. Cardiovasc Diabetol. 2006. PMID: 16700915 Free PMC article.

10

The effect of telmisartan on glucose and lipid metabolism in nondiabetic, insulin-resistant subjects.

Nagel JM, Tietz AB, Göke B, Parhofer KG. Nagel JM, et al. Among authors: parhofer kg. Metabolism. 2006 Sep;55(9):1149-54. doi: 10.1016/j.metabol.2006.04.011. Metabolism. 2006. PMID: 16919531 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

354 results

Search Page

Filters